Medical Access and Reimbursement in South Korea

Currently classified as a strictly controlled substance under South Korea's Narcotics Control Act, with no authorized medical use outside of approved clinical research. The national statute governs narcotics/psychotropic substances and criminalizes unauthorized manufacture, distribution, possession and use; access to psychedelics for therapy would require explicit regulatory authorization or a sanctioned clinical trial. # #

Currently classified as a strictly controlled substance under South Korea's Narcotics Control Act, with no authorized medical use outside of approved clinical research. MDMA possession, distribution and use are criminalized; any therapeutic access would require a formal, MFDS‑approved clinical trial or a change in scheduling/authorization by Korean authorities. #

Esketamine nasal spray (Spravato) received marketing authorization in South Korea for use in adults with treatment‑resistant depression (as an adjunct to an oral antidepressant) in 2020; the approval and domestic regulatory discussion were handled through the Ministry of Food and Drug Safety (MFDS) and related advisory bodies. Janssen announced local approval in June 2020 and Korean clinical/regulatory bodies have subsequently sought additional clinical data to support ongoing benefit/risk assessment. # #

Regulatory framework and delivery requirements: Esketamine is distributed and administered only within controlled medical settings because of acute safety concerns (dissociation, transient blood‑pressure increases, sedation). Domestic regulators have required post‑marketing data submissions and expert review to confirm clinical benefit in Korean populations. The MFDS/central pharmaceutical advisory processes and hospital safety infrastructure govern which institutions may store and administer esketamine, and clinicians must follow facility‑level monitoring and documentation standards consistent with international REMS‑style precautions. #

Reimbursement and access: Despite regulatory approval, esketamine in South Korea has been widely reported as a non‑reimbursed/high‑cost therapy in practice, making access largely private/out‑of‑pocket for many patients. Korean clinical commentary and practice reports note that high out‑of‑pocket cost and limited number of centers set up to administer intranasal esketamine constrain widespread uptake; discussions about national health insurance (NHIS) coverage or price negotiation have been reported but, as of the cited domestic coverage assessments, esketamine remained effectively accessed through private payment in many centers. # #

Note on classification and monitoring: Esketamine is treated differently from Schedule I classical psychedelics because it has an approved medical indication; however, it remains subject to strict institutional controls for safe administration and post‑marketing review by Korean regulators. #

Ketamine is an approved and legally used medical anesthetic and analgesic in South Korea, regulated for clinical use and supply under the national controlled‑substances framework; it is commonly used in hospitals for anesthesia and procedural sedation. At the same time, ketamine is classified as a controlled psychotropic drug for which unauthorized possession or recreational use is criminalized under the Narcotics Control Act. #

Psychiatric/off‑label use: In clinical psychiatry in South Korea, formulations of ketamine (typically IV or intramuscular injections, and sometimes intranasal or oral compounded preparations) are used off‑label by private clinics and hospital units to treat severe or treatment‑resistant depression, suicidal ideation and certain refractory pain conditions. This is an off‑label use rather than an MFDS‑approved psychiatric indication (esketamine is the MFDS‑approved, labeled product for TRD). Because ketamine psychiatric protocols vary by institution and are not a labeled antidepressant indication, reimbursement through Korea's national health insurance for ketamine when used as a psychiatric therapy is generally not standard; patients typically access these services in private or self‑pay settings, and protocols are implemented under institutional clinical governance and informed‑consent processes. # #

Regulation and safety: Because of abuse potential and documented harms associated with non‑medical use (including 'club drug' diversion), ketamine use is tightly controlled in supply chains, and institutions administering off‑label psychiatric ketamine generally require monitoring, patient screening and local institutional review/ethical oversight. Law enforcement and public health agencies have also reported rising seizures of ketamine in recreational contexts, underscoring the dual nature of ketamine as an important medical drug and a substance of misuse. #

Currently classified as a strictly controlled substance under South Korea's Narcotics Control Act, with no authorized medical use outside approved clinical research. Plant preparations containing DMT (e.g., ayahuasca) are likewise controlled by Korean narcotics/psychotropic laws and cannot be legally used or imported for personal/religious purposes absent special authorization. Any legal therapeutic or research access would require an MFDS‑sanctioned clinical trial or explicit regulatory change. #

Currently classified as a strictly controlled substance under South Korea's Narcotics Control Act, with no authorized medical use outside approved clinical research. 5‑MeO‑DMT (synthetic or derived from toad/plant sources) is treated as an illicit psychotropic agent under domestic law; possession, distribution or use outside authorized research is criminalized. #

Currently classified as a strictly controlled substance under South Korea's Narcotics Control Act, with no authorized medical use outside approved clinical research. Ibogaine is not an authorized treatment in South Korea and would only be accessible in the context of an approved clinical trial or a change in regulatory status. #

Ayahuasca (a DMT‑containing plant preparation) and other plant/ritual preparations containing controlled psychotropic substances are treated as illegal under the Narcotics Control Act; there is no lawful general access for religious or therapeutic purposes absent an explicit regulatory exception or an MFDS‑approved trial. Importation, possession or use can lead to criminal investigation. #

Currently classified as a strictly controlled substance under South Korea's Narcotics Control Act, with no authorized medical use outside approved clinical research. Mescaline (including peyote or other mescaline‑containing cacti) is subject to criminal regulation; ritual or religious exemptions common in a few other jurisdictions do not apply under current Korean law without explicit legal carve‑outs. #

Currently classified as a strictly controlled substance under South Korea's Narcotics Control Act, with no authorized medical use outside approved clinical research. The family of synthetic phenethylamine psychedelics (2C‑series) is illicit in South Korea; manufacture, importation, sale or possession are criminal offenses absent an approved research authorization. #